Novartis to buy Avidity Biosciences in $12 billion RNA therapeutics bet
ZURICH: Swiss drugmaker Novartis (NOVN.S) said on Sunday it has agreed to acquire U.S. biotech firm Avidity Biosciences (RNA.O) in a deal valued at approximately $12 billion, expanding its reach into the promising field of RNA therapeutics. Under the terms of the agreement, Novartis will pay $72 per share in cash for Avidity, representing a…